A test carried out during weeks 15-20 of the pregnancy, in which a small amount of the fluid that surrounds the fetus is removed for biochemical or genetic testing. It can assess whether the fetus could develop, or has developed, an abnormality or serious health condition.
Stem cells collected from amniotic fluid during pregnancy can be grown into organoids to study organ development and improve prenatal diagnosis of medical conditions...
A Texas court has awarded $100 million more damages to a company whose patents for non-invasive prenatal testing technology were infringed by a competitor...
A new rapid test can detect missing or extra chromosomes as part of prenatal and fertility care...
Prenatal genetic test results need to be communicated better, according to the US Food and Drug Administration...
A single blood drop, taken without your consent, can be life-changing...
A long-running court case over non-invasive prenatal testing patents has been settled...
Non-invasive prenatal testing (NIPT) was first introduced in 2011, when breakthroughs in sequencing technology allowed the analysis of cell-free fetal DNA(cffDNA) in maternal blood to detect genetic abnormalities in the foetus, such as trisomy 21 (Down
Jnetics and Chana shared their first joint event, with leading experts speaking about Jewish genetic disorder carrier screening, fertility advice and the reproductive options available to ensure genetic disorders are not passed onto future children...
The TedMed talk by Professor Alta Charo, entitled 'Should we fear gene editing?', highlights the progress made and the concerns raised in genetic research over the past fifty years...
Stay up-to-date on all the latest developments in the fields of human fertility and genomics. And be the first to hear about upcoming events and other announcements.
